Summary

The global antacids market comprises over-the-counter and prescription pharmaceutical agents designed to neutralize excess stomach acid and alleviate gastrointestinal symptoms like heartburn, indigestion, and acid reflux. Functioning primarily through basic compounds such as aluminum hydroxide, magnesium carbonate, calcium carbonate, and sodium bicarbonate these formulations deliver immediate, localized relief within the digestive tract. The relevance and importance of this industry lie in its role as a frontline, highly accessible self-care solution for common digestive ailments, preventing severe complications associated with chronic acid exposure, such as gastroesophageal reflux disease (GERD) and peptic ulcers. The primary growth drivers of the market include shifting dietary patterns marked by a higher consumption of processed, acidic, and fast foods alongside elevated stress levels, sedentary lifestyles, and rising global obesity rates. Additionally, an expanding global geriatric population naturally suffers from higher rates of age-related gastrointestinal issues, further accelerating demand. Growth is also fortified by robust retail expansion, rapid growth in e-commerce pharmacy distribution, and product innovations such as chewable tablets, soft-gels, flavored suspensions, and rapid-acting alginate formulations. Key industry activities focus on formulation R&D, strategic brand acquisitions, expanded over-the-counter accessibility, and geographic penetration into emerging markets. While the market does not have a single dedicated governing association, its trajectory and safety standards are actively shaped by broader pharmaceutical trade organizations such as the World Self-Medication Industry (WSMI), the Consumer Healthcare Products Association (CHPA), and the Association of the European Self-Medication Industry (AESGP) alongside regulatory oversight from global bodies like the U.S. FDA and WHO. Through continuous adaptation to self-medication trends, the antacids sector remains a vital, resilient anchor within the broader global consumer healthcare ecosystem. According to the research report, “Global Antacids Market Overview, 2031” published by Bonafide Research, the Global Antacids Market is expected to cross Global 10.46 Billion market size by 2031, with 4.12% CAGR by 2026-31.Prominent industry leaders driving commercial distribution include Haleon, Reckitt Benckiser, Bayer AG, Sanofi, Procter & Gamble, and Sun Pharmaceutical. Significant growth opportunities lie in expanding into high-growth emerging economies across the Asia-Pacific region, alongside accelerating consumer adoption of e-pharmacy channels. Innovations in product developments are actively shaping market trajectory, notably through the development of alginate-based raft-forming formulations that physically prevent reflux, faster-dissolving chewable soft-gels, and multi-action dual antacid-H2 blocker combination therapies. The antacids supply chain begins upstream with the bulk procurement of raw mineral compounds primarily calcium carbonate, magnesium hydroxide, aluminum hydroxide, and sodium bicarbonate alongside natural alginates derived from sea kelp. These active pharmaceutical ingredients (APIs) undergo stringent quality testing before moving to secondary processing, where they are blended with excipients, flavorings, and binders. Manufacturing operations require distinct production lines for solid dosage forms like chewable tablets (which command over 44% of market share) and liquid suspensions, which require specialized emulsification and tamper-evident bottling. Once packaged, finished goods transition through climate-controlled logistics networks managed by national pharmaceutical wholesalers. Distribution relies heavily on retail pharmacy chains and supermarket networks, which collectively handle over 70% of global volume. However, the supply chain is increasingly adapting to direct-to-consumer digital channels, where automated subscription services for recurring digestive health management are growing rapidly. Supply risks primarily stem from raw material price volatility, international freight bottlenecks, and regulatory compliance standards across different over-the-counter (OTC) trade regions. Market Drivers • Rising Global prevalence of lifestyle-induced gastrointestinal disorders: The primary growth driver for the global antacids market is the surging worldwide incidence of acid-related gastrointestinal conditions, particularly Gastroesophageal Reflux Disease (GERD), chronic heartburn, and non-ulcer dyspepsia. Modern lifestyle transformations defined by high consumption of ultra-processed, highly acidic, and spicy fast foods, combined with sedentary routines and rising global obesity rates have directly heightened stomach acid hypersecretion. Furthermore, modern work environments have led to elevated chronic stress levels, which impair mucosal barrier function and trigger gut-brain axis disruptions, compounding physical acid reflux issues. • Rapid shift toward self-medication culture: The market is heavily propelled by the entrenched global culture of consumer self-medication for minor or acute health ailments. Rather than navigating time-consuming primary physician appointments or securing prescriptions for transient digestive discomfort, consumers overwhelmingly favor fast-acting, over-the-counter (OTC) antacids. This behavioral shift is reinforced by aggressive retail expansion. Modern antacids are prominently placed not only in traditional retail drugstores and hospital pharmacies but also across non-pharmacy retail environments like hypermarkets, convenience stores, gas stations, and e-commerce platforms. Market Challenges • Intense competition from potent, longer-acting acid-suppressing alternatives: Traditional antacids face severe headwind from alternative, long-acting pharmaceutical drug classes specifically Proton Pump Inhibitors (PPIs like omeprazole and esomeprazole) and H2-Receptor Antagonists (H2RAs like famotidine). While conventional antacids act rapidly by neutralizing active gastric acid in the short term, their therapeutic duration is brief. In contrast, PPIs and H2 block acid production at the systemic or cellular source, offering 12- to 24-hour symptom prevention for chronic conditions. • Health risks associated with long-term overuse & stricter regulatory warnings: Because antacids are easily obtainable without professional medical oversight, chronic misuse presents notable physiological risks that threaten market expansion. Prolonged or high-dose ingestion of calcium-, aluminum-, or magnesium-based antacids can trigger systemic side effects, including hypercalcemia, metabolic alkalosis, severe constipation, diarrhea, and impaired renal function. Excessive sodium bicarbonate intake also poses risks for hypernatremia and hypertension. In response, global regulatory authorities (such as the U.S. FDA and EMA) have introduced stricter packaging disclosure mandates warning consumers against long-term self-medication. Market Trends • Transition from simple acid neutralizers to alginate-based reflux raft formulations: A major evolution in antacid product design is the commercial pivot from traditional chemical neutralizers (e.g., simple calcium carbonate or magnesium hydroxide) toward advanced alginate-based formulations. Modern premium antacids increasingly combine low-dose neutralizing salts with natural sodium alginate extracted from brown sea kelp. Upon reacting with stomach acid, the alginate forms a thick, neutral, gel-like barrier a physical raft that floats on top of the gastric contents. This physical raft acts as a mechanical plug at the gastroesophageal junction, physically preventing acid, pepsin, and bile from refluxing into the esophagus. • Delivery innovation & consumer-centric convenience formats: Manufacturers are investing heavily in re-engineering antacid dosage formats to overcome historical consumer pain points, such as chalky textures, bitter aftertastes, and inconvenient administration. The market is witnessing a clear shift toward consumer-friendly delivery systems, such as fast-melting chewable soft-gels, gummy formulations, multi-flavored effervescent granules, and portable single-serve liquid sachets. These user-centric formats eliminate the need for water, catering directly to active, on-the-go consumers seeking discrete and palatable relief. Proton pump inhibitors are the leading drug-class segment because they provide strong and sustained suppression of gastric acid and are a standard treatment option for GERD, including frequent heartburn and erosive esophagitis. Proton pump inhibitors (PPIs) occupy a prominent position because their pharmacological action directly addresses excessive gastric acid production, which is central to many reflux-related conditions. Unlike conventional antacids that mainly neutralize acid already present in the stomach, PPIs inhibit the gastric hydrogen-potassium ATPase, commonly known as the proton pump, thereby reducing acid secretion at its final stage. This makes them particularly useful when symptoms occur frequently or when acid exposure has resulted in esophageal inflammation. Clinical guidance from the American College of Gastroenterology identifies PPIs as the main medical therapy for gastroesophageal reflux disease and recommends them for appropriate patients with GERD; continued PPI therapy is also recommended for patients with more advanced erosive esophagitis. Their clinical relevance is reinforced by the high occurrence of reflux symptoms in Western populations and the substantial burden of GERD in North America. A systematic review reported GERD prevalence estimates of 18.1% to 27.8% in North America, while another global meta-analysis found the highest regional pooled prevalence in North America. PPIs are also used across different treatment settings, ranging from physician-directed management to products available without prescription in some countries. Their ability to provide prolonged acid suppression makes them suitable for recurrent symptoms rather than only occasional acid discomfort. In addition, PPIs have established roles in healing acid-related mucosal injury and maintaining healing in patients who require ongoing acid control. Tablets and chewables lead the dosage-form segment because they combine portability, convenient administration, accurate dosing, and rapid consumer access, making them particularly suitable for self-treatment of intermittent heartburn and acid indigestion. Tablets and chewable formulations are widely suited to the practical way consumers manage occasional digestive discomfort because they can be carried, stored, and administered without measuring equipment or preparation. Conventional tablets provide a familiar oral dosage format with a defined amount of active ingredient, while chewable tablets are especially useful when a consumer wants to take a product without water or has difficulty swallowing intact tablets. The U.S. Food and Drug Administration describes chewable tablets as oral dosage forms intended to be chewed before swallowing and notes that they can be designed to be palatable and easy to use by pediatric, adult, and elderly populations, including people who are unable or reluctant to swallow intact tablets. This practical advantage is particularly relevant to antacid products because many are intended for use when symptoms appear rather than at a fixed time each day. FDA's OTC antacid monograph specifically permits labeling for relief of heartburn, sour stomach, and acid indigestion, while dosage directions are commonly expressed in tablet units, reinforcing the suitability of solid oral formats for self-care. Actual U.S. regulatory records also show numerous antacid products marketed as chewable tablets, including formulations containing aluminum hydroxide and magnesium carbonate and combination products containing antacid ingredients. Chewable products can also support convenient administration during travel, work, meals, or other situations where liquids may be inconvenient. Their unit-dose nature helps consumers follow labeled instructions without estimating quantities from a bottle or spoon. Furthermore, tablets generally have good storage stability and can be packaged in bottles, blister packs, or portable containers, making distribution and household use straightforward. Heartburn is the largest indication because it is the defining symptom of acid reflux and GERD and is one of the most common reasons consumers seek antacid and acid-reducing treatment. Heartburn has a particularly strong connection with the antacid category because antacids are specifically intended to relieve the burning discomfort associated with gastric acid moving into the esophagus. The symptom is closely linked with gastroesophageal reflux disease, a condition characterized by reflux of stomach contents that can produce heartburn and regurgitation. The National Institute of Diabetes and Digestive and Kidney Diseases identifies heartburn as a major symptom of GERD and reports that approximately 20% of people in the United States have GERD. Medical literature also shows that heartburn is common across Western populations. A systematic review found that approximately 25% of people in Western populations experienced heartburn at least once per month, around 12% experienced it at least weekly, and about 5% experienced it daily. Another review reported weekly heartburn or reflux prevalence estimates of 18% to 28% in North America. These patterns create a broad need for products that can address episodic symptoms as well as recurring reflux-related discomfort. Antacid products are particularly relevant for mild, intermittent GERD-associated heartburn because their mechanism involves neutralizing gastric acid and reducing acidity in the stomach. FDA's OTC antacid monograph also specifically identifies heartburn, sour stomach, and acid indigestion as conditions for which qualifying antacid products may be labeled for relief. Heartburn is therefore not simply another indication within the category; it is directly tied to the primary consumer-recognized symptom for which these products are purchased. Retail pharmacies lead the distribution channel because they combine broad consumer accessibility with immediate availability of nonprescription antacids and the opportunity for pharmacist guidance when consumers need product-selection support. Retail pharmacies are particularly important for antacids because these products are frequently purchased for immediate or short-term relief rather than as part of a planned long-term treatment program. Antacids are generally nonprescription medicines, meaning consumers can obtain them without first visiting a physician, which naturally supports distribution through easily accessible retail pharmacy locations. Clinical references describe antacids as medications that do not require a prescription and are commonly self-selected for mild, intermittent GERD-associated heartburn. This self-care characteristic makes the pharmacy an important point of access because consumers can identify a symptom, visit a pharmacy, compare several formulations, and purchase an appropriate product during the same interaction. Retail pharmacies also provide a useful setting for pharmacist involvement, particularly when consumers are uncertain about active ingredients, dosage, drug interactions, or whether persistent symptoms warrant medical assessment. FDA labeling for antacid products includes specific restrictions and warnings, including limits on maximum daily use and recommendations to seek medical advice when symptoms persist beyond the specified period. Such requirements make the pharmacy environment valuable because consumers can receive basic medication-use guidance alongside product availability. The channel also accommodates a broad range of formulations, including chewable tablets, liquids, combination acid reducers, and other oral preparations. FDA regulatory records demonstrate the presence of numerous antacid products in retail-oriented brands and formulations, including products associated with pharmacy and retail chains. Retail pharmacies further benefit from their proximity to residential communities and their established role in everyday healthcare purchasing. Unlike channels that may involve shipping or advance ordering, physical pharmacies can satisfy an immediate need when heartburn occurs after meals or during travel. North America leads the regional segment because the region has a high documented burden of GERD and reflux symptoms, strong awareness of digestive health, and extensive access to prescription and over-the-counter acid-reducing therapies. North America's leading position can be linked primarily to the comparatively high occurrence of gastroesophageal reflux disease and heartburn documented in population-based research. A systematic review of GERD epidemiology found prevalence estimates ranging from 18.1% to 27.8% in North America, higher than the ranges reported for several other major geographic regions in the same analysis. A later global systematic review and meta-analysis similarly reported the highest pooled regional prevalence of gastroesophageal reflux disease in North America, at 19.55%, compared with lower levels in several Asian regions. The United States alone has a substantial burden of GERD, with the National Institute of Diabetes and Digestive and Kidney Diseases estimating that about one in five people in the country has the condition. The region also has a long-established healthcare infrastructure in which both prescription acid-suppressing medicines and nonprescription products are widely used. Proton pump inhibitors have been described in medical literature as the mainstay of GERD medical therapy for several decades, while antacids and other OTC therapies remain useful for symptomatic relief. North American consumers also have access to numerous dosage forms and product combinations, including chewable antacids and combination acid reducer-antacid products. FDA records demonstrate continued availability of multiple OTC antacid formulations in the U.S. market. • USA: The United States is the largest regional market because its large adult population, substantial burden of GERD, mature OTC medicine system, and extensive consumer access to acid-reducing treatments create strong underlying demand for antacid products. NIDDK estimates that approximately 20% of people in the United States have GERD, establishing a significant clinical population affected by a condition closely associated with heartburn and acid reflux. • June 2026: Bayer India launched Alka-Seltzer in India as an effervescent antacid in single-use sachets that incorporates Lactobacillus probiotics. The new positioning expands antacid use from episodic symptom relief to a gut-health adjacent self-care proposition, increasing competitive pressure on local and multinational OTC portfolios to add differentiated claims and formats. • January 2026: Wonderbelly, one of the digestive health company, engaged in clean-label product developments, was acquired by Procter & Gamble. Becoming part of P&G’s personal health care portfolio, Wonderbelly is expected to strengthen P&G position in consumer health industry. • August 2025: Mankind Pharma launched a marketing campaign for its Gas-O-Fast antacid brand focused on local solutions for digestive issues. The new campaign proudly positions the product as the Asli Indian Solution. • July 2025: Abbott introduced Digene Insta on the Go, a ready-to-use and water-free antacid solution to provide quick relief from heartburn, acidity, and indigestion. The product provides relief in just two seconds and is aimed at people looking for convenience while managing gastrointestinal discomfort. • June 2025: The FDA published draft guidance permitting simple OTC monograph change that gave manufacturers the liberty to change their product from tablet to chewable or film without separate orders and to accelerate the speed of reformulations. • January 2025: Haleon, the prominent healthcare firm based in the UK, revealed intentions to invest USD 54 Million to enhance its research and development (R&D) facility in Northside Richmond, Virginia. The enhancements were anticipated to finish in 2025, with the updated plant projected to be functional later that year, boosting Haleon’s R&D capabilities for upcoming innovations. • April 2025: GSK entered into a USD 2.2 billion mediation settlement to resolve 93% of litigation concerning Zantac and reduce surrounding legal risk clouds and uncertainties for the total antacids category. • April 2025: Sebela Pharmaceuticals announced favorable Phase 3 study results for tegoprazan, a P-CAB that demonstrated to be statistically superior to lansoprazole, with a planned FDA submission for Q4 2025. • April 2025: Sanofi completed the sale of a 50.0% controlling stake in its consumer healthcare business, Opella, to Clayton, Dubilier & Rice (CD&R). The transaction increases the likelihood of sharper capital allocation and tighter portfolio focus within large OTC digestive-health lines, given that Opella operates with a more independent ownership structure. • August 2024: ENO by Haleon, India's top OTC antacid brand, introduced its new 3-in-1 antacid variant made from ENO, cumin, carom seeds, and black salt for rapid and effective relief. The innovative item alleviated gastric unease, acidity, and indigestion. • July 2024: The US Food and Drug Administration (FDA) authorized a novel therapy for GERD. The new medication, vonoprazan (Voquezna), was to be used daily to alleviate heartburn due to GERD in adults. • July 2024: Phathom Pharmaceuticals, a biopharmaceutical company dedicated to the development and market launch of next-generation therapies for gastric acid disorders, announced the approval of the FDA for VOQUEZNA (vonoprazan) 10 mg tablets, which are used to reduce the heartburn related to Gastroesophageal Reflux Disease (GERD) in adults. Considered in this report • Historic Year: 2020 • Base year: 2025 • Estimated year: 2026 • Forecast year: 2031 Aspects covered in this report • Antacids Market with its value and forecast along with its segments • Various drivers and challenges • On-going trends and developments • Top profiled companies • Strategic recommendation By Drug Class • Acid Neutralizers • Proton Pump Inhibitors (PPIs) • H2 Antagonists • Pro-Motility Agents • Combination Formulations By Dosage Form • Tablets & Chewables • Liquid Suspensions • Powders • Gels & Syrups • Gummies & Other By Indication • Gastroesophageal Reflux Disease • Heartburn • Peptic Ulcer • Others By Distribution Channel • Retail Pharmacies • Hospital Pharmacies • Online Pharmacies / E-Commerce ***Please Note: It will take 48 hours (2 Business days) for delivery of the report upon order confirmation.

ページTOPに戻る

Table of Contents

Table of Content



1. Executive Summary

2. Market Dynamics

2.1. Market Drivers & Opportunities

2.2. Market Restraints & Challenges

2.3. Market Trends

2.4. Supply chain Analysis

2.5. Policy & Regulatory Framework

2.6. Industry Experts Views

3. Research Methodology

3.1. Secondary Research

3.2. Primary Data Collection

3.3. Market Formation & Validation

3.4. Report Writing, Quality Check & Delivery

4. Market Structure

4.1. Market Considerate

4.2. Assumptions

4.3. Limitations

4.4. Abbreviations

4.5. Sources

4.6. Definitions

5. Economic /Demographic Snapshot

6. Global Antacids Market Outlook

6.1. Market Size By Value

6.2. Market Share By Region

6.3. Market Size and Forecast, By Geography

6.4. Market Size and Forecast, By Drug Class

6.5. Market Size and Forecast, By Dosage Form

6.6. Market Size and Forecast, By Indication

6.7. Market Size and Forecast, By Distribution Channel

7. North America Antacids Market Outlook

7.1. Market Size By Value

7.2. Market Share By Country

7.3. Market Size and Forecast, By Drug Class

7.4. Market Size and Forecast, By Dosage Form

7.5. Market Size and Forecast, By Indication

7.6. Market Size and Forecast, By Distribution Channel

7.7. United States Antacids Market Outlook

7.7.1. Market Size by Value

7.7.2. Market Size and Forecast By Drug Class

7.7.3. Market Size and Forecast By Dosage Form

7.7.4. Market Size and Forecast By Indication

7.7.5. Market Size and Forecast By Distribution Channel

7.8. Canada Antacids Market Outlook

7.8.1. Market Size by Value

7.8.2. Market Size and Forecast By Drug Class

7.8.3. Market Size and Forecast By Dosage Form

7.8.4. Market Size and Forecast By Indication

7.8.5. Market Size and Forecast By Distribution Channel

7.9. Mexico Antacids Market Outlook

7.9.1. Market Size by Value

7.9.2. Market Size and Forecast By Drug Class

7.9.3. Market Size and Forecast By Dosage Form

7.9.4. Market Size and Forecast By Indication

7.9.5. Market Size and Forecast By Distribution Channel

8. Europe Antacids Market Outlook

8.1. Market Size By Value

8.2. Market Share By Country

8.3. Market Size and Forecast, By Drug Class

8.4. Market Size and Forecast, By Dosage Form

8.5. Market Size and Forecast, By Indication

8.6. Market Size and Forecast, By Distribution Channel

8.7. Germany Antacids Market Outlook

8.7.1. Market Size by Value

8.7.2. Market Size and Forecast By Drug Class

8.7.3. Market Size and Forecast By Dosage Form

8.7.4. Market Size and Forecast By Indication

8.7.5. Market Size and Forecast By Distribution Channel

8.8. United Kingdom (UK) Antacids Market Outlook

8.8.1. Market Size by Value

8.8.2. Market Size and Forecast By Drug Class

8.8.3. Market Size and Forecast By Dosage Form

8.8.4. Market Size and Forecast By Indication

8.8.5. Market Size and Forecast By Distribution Channel

8.9. France Antacids Market Outlook

8.9.1. Market Size by Value

8.9.2. Market Size and Forecast By Drug Class

8.9.3. Market Size and Forecast By Dosage Form

8.9.4. Market Size and Forecast By Indication

8.9.5. Market Size and Forecast By Distribution Channel

8.10. Italy Antacids Market Outlook

8.10.1. Market Size by Value

8.10.2. Market Size and Forecast By Drug Class

8.10.3. Market Size and Forecast By Dosage Form

8.10.4. Market Size and Forecast By Indication

8.10.5. Market Size and Forecast By Distribution Channel

8.11. Spain Antacids Market Outlook

8.11.1. Market Size by Value

8.11.2. Market Size and Forecast By Drug Class

8.11.3. Market Size and Forecast By Dosage Form

8.11.4. Market Size and Forecast By Indication

8.11.5. Market Size and Forecast By Distribution Channel

8.12. Russia Antacids Market Outlook

8.12.1. Market Size by Value

8.12.2. Market Size and Forecast By Drug Class

8.12.3. Market Size and Forecast By Dosage Form

8.12.4. Market Size and Forecast By Indication

8.12.5. Market Size and Forecast By Distribution Channel

9. Asia-Pacific Antacids Market Outlook

9.1. Market Size By Value

9.2. Market Share By Country

9.3. Market Size and Forecast, By Drug Class

9.4. Market Size and Forecast, By Dosage Form

9.5. Market Size and Forecast, By Indication

9.6. Market Size and Forecast, By Distribution Channel

9.7. China Antacids Market Outlook

9.7.1. Market Size by Value

9.7.2. Market Size and Forecast By Drug Class

9.7.3. Market Size and Forecast By Dosage Form

9.7.4. Market Size and Forecast By Indication

9.7.5. Market Size and Forecast By Distribution Channel

9.8. Japan Antacids Market Outlook

9.8.1. Market Size by Value

9.8.2. Market Size and Forecast By Drug Class

9.8.3. Market Size and Forecast By Dosage Form

9.8.4. Market Size and Forecast By Indication

9.8.5. Market Size and Forecast By Distribution Channel

9.9. India Antacids Market Outlook

9.9.1. Market Size by Value

9.9.2. Market Size and Forecast By Drug Class

9.9.3. Market Size and Forecast By Dosage Form

9.9.4. Market Size and Forecast By Indication

9.9.5. Market Size and Forecast By Distribution Channel

9.10. Australia Antacids Market Outlook

9.10.1. Market Size by Value

9.10.2. Market Size and Forecast By Drug Class

9.10.3. Market Size and Forecast By Dosage Form

9.10.4. Market Size and Forecast By Indication

9.10.5. Market Size and Forecast By Distribution Channel

9.11. South Korea Antacids Market Outlook

9.11.1. Market Size by Value

9.11.2. Market Size and Forecast By Drug Class

9.11.3. Market Size and Forecast By Dosage Form

9.11.4. Market Size and Forecast By Indication

9.11.5. Market Size and Forecast By Distribution Channel

10. South America Antacids Market Outlook

10.1. Market Size By Value

10.2. Market Share By Country

10.3. Market Size and Forecast, By Drug Class

10.4. Market Size and Forecast, By Dosage Form

10.5. Market Size and Forecast, By Indication

10.6. Market Size and Forecast, By Distribution Channel

10.7. Brazil Antacids Market Outlook

10.7.1. Market Size by Value

10.7.2. Market Size and Forecast By Drug Class

10.7.3. Market Size and Forecast By Dosage Form

10.7.4. Market Size and Forecast By Indication

10.7.5. Market Size and Forecast By Distribution Channel

10.8. Argentina Antacids Market Outlook

10.8.1. Market Size by Value

10.8.2. Market Size and Forecast By Drug Class

10.8.3. Market Size and Forecast By Dosage Form

10.8.4. Market Size and Forecast By Indication

10.8.5. Market Size and Forecast By Distribution Channel

10.9. Colombia Antacids Market Outlook

10.9.1. Market Size by Value

10.9.2. Market Size and Forecast By Drug Class

10.9.3. Market Size and Forecast By Dosage Form

10.9.4. Market Size and Forecast By Indication

10.9.5. Market Size and Forecast By Distribution Channel

11. Middle East & Africa Antacids Market Outlook

11.1. Market Size By Value

11.2. Market Share By Country

11.3. Market Size and Forecast, By Drug Class

11.4. Market Size and Forecast, By Dosage Form

11.5. Market Size and Forecast, By Indication

11.6. Market Size and Forecast, By Distribution Channel

11.7. United Arab Emirates (UAE) Antacids Market Outlook

11.7.1. Market Size by Value

11.7.2. Market Size and Forecast By Drug Class

11.7.3. Market Size and Forecast By Dosage Form

11.7.4. Market Size and Forecast By Indication

11.7.5. Market Size and Forecast By Distribution Channel

11.8. Saudi Arabia Antacids Market Outlook

11.8.1. Market Size by Value

11.8.2. Market Size and Forecast By Drug Class

11.8.3. Market Size and Forecast By Dosage Form

11.8.4. Market Size and Forecast By Indication

11.8.5. Market Size and Forecast By Distribution Channel

11.9. South Africa Antacids Market Outlook

11.9.1. Market Size by Value

11.9.2. Market Size and Forecast By Drug Class

11.9.3. Market Size and Forecast By Dosage Form

11.9.4. Market Size and Forecast By Indication

11.9.5. Market Size and Forecast By Distribution Channel

12. Competitive Landscape

12.1. Competitive Dashboard

12.2. Business Strategies Adopted by Key Players

12.3. Key Players Market Share Insights and Analysis, 2025

12.4. Key Players Market Positioning Matrix

12.5. Porter's Five Forces

12.6. Company Profile

12.6.1. Abbott Laboratories

12.6.1.1. Company Snapshot

12.6.1.2. Company Overview

12.6.1.3. Financial Highlights

12.6.1.4. Geographic Insights

12.6.1.5. Business Segment & Performance

12.6.1.6. Product Portfolio

12.6.1.7. Key Executives

12.6.1.8. Strategic Moves & Developments

12.6.2. Sun Pharmaceutical Industries Ltd.

12.6.3. Sanofi S.A.

12.6.4. Pfizer Inc.

12.6.5. Reckitt Benckiser Group PLC

12.6.6. Haleon Plc

12.6.7. Teva Pharmaceutical Industries

12.6.8. GSK plc.

12.6.9. AstraZeneca Plc

12.6.10. Procter & Gamble Co.

12.6.11. Takeda Pharmaceutical Company Ltd.

12.6.12. WellSpring Pharmaceutical Corporation

12.6.13. Perrigo Company Plc

12.6.14. Dr. Reddy's Laboratories Ltd.

12.6.15. CVS Health Corporation

12.6.16. Bayer AG

12.6.17. Advance Pharmaceutical Inc.

12.6.18. AdvaCare Pharma

12.6.19. Akums Drugs & Pharmaceuticals Ltd.

12.6.20. Adcock Ingram Holdings Ltd.

13. Strategic Recommendations

14. Annexure

14.1. FAQ`s

14.2. Notes

15. Disclaimer

ページTOPに戻る

List of Tables/Graphs

List of Figure



Figure 1: Global Antacids Market Size (USD Billion) By Region, 2025 & 2031F

Figure 2: Market attractiveness Index, By Region 2031F

Figure 3: Market attractiveness Index, By Segment 2031F

Figure 4: Global Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 5: Global Antacids Market Share By Region (2025)

Figure 6: North America Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 7: North America Antacids Market Share By Country (2025)

Figure 8: US Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 9: Canada Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 10: Mexico Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 11: Europe Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 12: Europe Antacids Market Share By Country (2025)

Figure 13: Germany Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 14: United Kingdom (UK) Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 15: France Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 16: Italy Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 17: Spain Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 18: Russia Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 19: Asia-Pacific Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 20: Asia-Pacific Antacids Market Share By Country (2025)

Figure 21: China Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 22: Japan Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 23: India Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 24: Australia Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 25: South Korea Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 26: South America Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 27: South America Antacids Market Share By Country (2025)

Figure 28: Brazil Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 29: Argentina Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 30: Colombia Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 31: Middle East & Africa Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 32: Middle East & Africa Antacids Market Share By Country (2025)

Figure 33: United Arab Emirates (UAE) Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 34: Saudi Arabia Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 35: South Africa Antacids Market Size By Value (2020, 2025 & 2031F) (in USD Billion)

Figure 36: Porter's Five Forces of Global Antacids Market





List of Table



Table 1: Global Antacids Market Snapshot, By Segmentation (2025 & 2031F) (in USD Billion)

Table 2: Influencing Factors for Antacids Market, 2025

Table 3: Top 10 Counties Economic Snapshot 2024

Table 4: Economic Snapshot of Other Prominent Countries 2022

Table 5: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars

Table 6: Global Antacids Market Size and Forecast, By Geography (2020 to 2031F) (In USD Billion)

Table 7: Global Antacids Market Size and Forecast, By Drug Class (2020 to 2031F) (In USD Billion)

Table 8: Global Antacids Market Size and Forecast, By Dosage Form (2020 to 2031F) (In USD Billion)

Table 9: Global Antacids Market Size and Forecast, By Indication (2020 to 2031F) (In USD Billion)

Table 10: Global Antacids Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 11: North America Antacids Market Size and Forecast, By Drug Class (2020 to 2031F) (In USD Billion)

Table 12: North America Antacids Market Size and Forecast, By Dosage Form (2020 to 2031F) (In USD Billion)

Table 13: North America Antacids Market Size and Forecast, By Indication (2020 to 2031F) (In USD Billion)

Table 14: North America Antacids Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 15: United States Antacids Market Size and Forecast By Drug Class (2020 to 2031F) (In USD Billion)

Table 16: United States Antacids Market Size and Forecast By Dosage Form (2020 to 2031F) (In USD Billion)

Table 17: United States Antacids Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)

Table 18: United States Antacids Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 19: Canada Antacids Market Size and Forecast By Drug Class (2020 to 2031F) (In USD Billion)

Table 20: Canada Antacids Market Size and Forecast By Dosage Form (2020 to 2031F) (In USD Billion)

Table 21: Canada Antacids Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)

Table 22: Canada Antacids Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 23: Mexico Antacids Market Size and Forecast By Drug Class (2020 to 2031F) (In USD Billion)

Table 24: Mexico Antacids Market Size and Forecast By Dosage Form (2020 to 2031F) (In USD Billion)

Table 25: Mexico Antacids Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)

Table 26: Mexico Antacids Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 27: Europe Antacids Market Size and Forecast, By Drug Class (2020 to 2031F) (In USD Billion)

Table 28: Europe Antacids Market Size and Forecast, By Dosage Form (2020 to 2031F) (In USD Billion)

Table 29: Europe Antacids Market Size and Forecast, By Indication (2020 to 2031F) (In USD Billion)

Table 30: Europe Antacids Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 31: Germany Antacids Market Size and Forecast By Drug Class (2020 to 2031F) (In USD Billion)

Table 32: Germany Antacids Market Size and Forecast By Dosage Form (2020 to 2031F) (In USD Billion)

Table 33: Germany Antacids Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)

Table 34: Germany Antacids Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 35: United Kingdom (UK) Antacids Market Size and Forecast By Drug Class (2020 to 2031F) (In USD Billion)

Table 36: United Kingdom (UK) Antacids Market Size and Forecast By Dosage Form (2020 to 2031F) (In USD Billion)

Table 37: United Kingdom (UK) Antacids Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)

Table 38: United Kingdom (UK) Antacids Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 39: France Antacids Market Size and Forecast By Drug Class (2020 to 2031F) (In USD Billion)

Table 40: France Antacids Market Size and Forecast By Dosage Form (2020 to 2031F) (In USD Billion)

Table 41: France Antacids Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)

Table 42: France Antacids Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 43: Italy Antacids Market Size and Forecast By Drug Class (2020 to 2031F) (In USD Billion)

Table 44: Italy Antacids Market Size and Forecast By Dosage Form (2020 to 2031F) (In USD Billion)

Table 45: Italy Antacids Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)

Table 46: Italy Antacids Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 47: Spain Antacids Market Size and Forecast By Drug Class (2020 to 2031F) (In USD Billion)

Table 48: Spain Antacids Market Size and Forecast By Dosage Form (2020 to 2031F) (In USD Billion)

Table 49: Spain Antacids Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)

Table 50: Spain Antacids Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 51: Russia Antacids Market Size and Forecast By Drug Class (2020 to 2031F) (In USD Billion)

Table 52: Russia Antacids Market Size and Forecast By Dosage Form (2020 to 2031F) (In USD Billion)

Table 53: Russia Antacids Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)

Table 54: Russia Antacids Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 55: Asia-Pacific Antacids Market Size and Forecast, By Drug Class (2020 to 2031F) (In USD Billion)

Table 56: Asia-Pacific Antacids Market Size and Forecast, By Dosage Form (2020 to 2031F) (In USD Billion)

Table 57: Asia-Pacific Antacids Market Size and Forecast, By Indication (2020 to 2031F) (In USD Billion)

Table 58: Asia-Pacific Antacids Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 59: China Antacids Market Size and Forecast By Drug Class (2020 to 2031F) (In USD Billion)

Table 60: China Antacids Market Size and Forecast By Dosage Form (2020 to 2031F) (In USD Billion)

Table 61: China Antacids Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)

Table 62: China Antacids Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 63: Japan Antacids Market Size and Forecast By Drug Class (2020 to 2031F) (In USD Billion)

Table 64: Japan Antacids Market Size and Forecast By Dosage Form (2020 to 2031F) (In USD Billion)

Table 65: Japan Antacids Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)

Table 66: Japan Antacids Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 67: India Antacids Market Size and Forecast By Drug Class (2020 to 2031F) (In USD Billion)

Table 68: India Antacids Market Size and Forecast By Dosage Form (2020 to 2031F) (In USD Billion)

Table 69: India Antacids Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)

Table 70: India Antacids Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 71: Australia Antacids Market Size and Forecast By Drug Class (2020 to 2031F) (In USD Billion)

Table 72: Australia Antacids Market Size and Forecast By Dosage Form (2020 to 2031F) (In USD Billion)

Table 73: Australia Antacids Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)

Table 74: Australia Antacids Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 75: South Korea Antacids Market Size and Forecast By Drug Class (2020 to 2031F) (In USD Billion)

Table 76: South Korea Antacids Market Size and Forecast By Dosage Form (2020 to 2031F) (In USD Billion)

Table 77: South Korea Antacids Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)

Table 78: South Korea Antacids Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 79: South America Antacids Market Size and Forecast, By Drug Class (2020 to 2031F) (In USD Billion)

Table 80: South America Antacids Market Size and Forecast, By Dosage Form (2020 to 2031F) (In USD Billion)

Table 81: South America Antacids Market Size and Forecast, By Indication (2020 to 2031F) (In USD Billion)

Table 82: South America Antacids Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 83: Brazil Antacids Market Size and Forecast By Drug Class (2020 to 2031F) (In USD Billion)

Table 84: Brazil Antacids Market Size and Forecast By Dosage Form (2020 to 2031F) (In USD Billion)

Table 85: Brazil Antacids Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)

Table 86: Brazil Antacids Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 87: Argentina Antacids Market Size and Forecast By Drug Class (2020 to 2031F) (In USD Billion)

Table 88: Argentina Antacids Market Size and Forecast By Dosage Form (2020 to 2031F) (In USD Billion)

Table 89: Argentina Antacids Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)

Table 90: Argentina Antacids Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 91: Colombia Antacids Market Size and Forecast By Drug Class (2020 to 2031F) (In USD Billion)

Table 92: Colombia Antacids Market Size and Forecast By Dosage Form (2020 to 2031F) (In USD Billion)

Table 93: Colombia Antacids Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)

Table 94: Colombia Antacids Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 95: Middle East & Africa Antacids Market Size and Forecast, By Drug Class (2020 to 2031F) (In USD Billion)

Table 96: Middle East & Africa Antacids Market Size and Forecast, By Dosage Form (2020 to 2031F) (In USD Billion)

Table 97: Middle East & Africa Antacids Market Size and Forecast, By Indication (2020 to 2031F) (In USD Billion)

Table 98: Middle East & Africa Antacids Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 99: United Arab Emirates (UAE) Antacids Market Size and Forecast By Drug Class (2020 to 2031F) (In USD Billion)

Table 100: United Arab Emirates (UAE) Antacids Market Size and Forecast By Dosage Form (2020 to 2031F) (In USD Billion)

Table 101: United Arab Emirates (UAE) Antacids Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)

Table 102: United Arab Emirates (UAE) Antacids Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 103: Saudi Arabia Antacids Market Size and Forecast By Drug Class (2020 to 2031F) (In USD Billion)

Table 104: Saudi Arabia Antacids Market Size and Forecast By Dosage Form (2020 to 2031F) (In USD Billion)

Table 105: Saudi Arabia Antacids Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)

Table 106: Saudi Arabia Antacids Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 107: South Africa Antacids Market Size and Forecast By Drug Class (2020 to 2031F) (In USD Billion)

Table 108: South Africa Antacids Market Size and Forecast By Dosage Form (2020 to 2031F) (In USD Billion)

Table 109: South Africa Antacids Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)

Table 110: South Africa Antacids Market Size and Forecast By Distribution Channel (2020 to 2031F) (In USD Billion)

Table 111: Competitive Dashboard of top 5 players, 2025

Table 112: Key Players Market Share Insights and Analysis for Antacids Market 2025